
Caroline J Coats

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3931844/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Calculated plasma volume status and prognosis in chronic heart failure. European Journal of Heart Failure, 2015, 17, 35-43.	2.9	104
2	Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. European Heart Journal, 2013, 34, 2529-2537.	1.0	84
3	Cardiopulmonary Exercise Testing and Prognosis in Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2015, 8, 1022-1031.	1.6	79
4	Clinical and genetic predictors of major cardiac events in patients with Anderson–Fabry Disease. Heart, 2015, 101, 961-966.	1.2	78
5	Expansion of the red cell distribution width and evolving iron deficiency as predictors of poor outcome in chronic heart failure. International Journal of Cardiology, 2013, 168, 1997-2002.	0.8	72
6	Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease. Europace, 2011, 13, 1781-1788.	0.7	63
7	Role of Serum N-Terminal Pro-Brain Natriuretic Peptide Measurement in Diagnosis of Cardiac Involvement in Patients With Anderson-Fabry Disease. American Journal of Cardiology, 2013, 111, 111-117.	0.7	54
8	Proteomic Analysis of the Myocardium in Hypertrophic Obstructive Cardiomyopathy. Circulation Genomic and Precision Medicine, 2018, 11, e001974.	1.6	38
9	Exercise-Induced Left Ventricular Outflow Tract Obstruction in Symptomatic Patients With Anderson-Fabry Disease. Journal of the American College of Cardiology, 2011, 58, 88-89.	1.2	34
10	Identification of a Multiplex Biomarker Panel for Hypertrophic Cardiomyopathy Using Quantitative Proteomics and Machine Learning. Molecular and Cellular Proteomics, 2020, 19, 114-127.	2.5	32
11	Arrhythmogenic Left Ventricular Cardiomyopathy. Circulation, 2009, 120, 2613-2614.	1.6	31
12	Pregnancy and its management in women with GSD type III ―a single centre experience. Journal of Inherited Metabolic Disease, 2012, 35, 245-251.	1.7	25
13	Genetic biomarkers in hypertrophic cardiomyopathy. Biomarkers in Medicine, 2013, 7, 505-516.	0.6	24
14	Somatic <i>MYH7</i> , <i>MYBPC3</i> , <i>TPM1</i> , <i>TNNT2</i> and <i>TNNI3</i> Mutations in Sporadic Hypertrophic Cardiomyopathy. Circulation Journal, 2013, 77, 2358-2365.	0.7	15
15	Peripartum cardiomyopathy: diagnosis and management. Heart, 2018, 104, 779-786.	1.2	14
16	Current applications of biomarkers in cardiomyopathies. Expert Review of Cardiovascular Therapy, 2015, 13, 825-837.	0.6	13
17	Familial dilated cardiomyopathy associated with pathogenic <scp><i>TBX5</i></scp> variants: Expanding the cardiac phenotype associated with <scp>Holt–Oram</scp> syndrome. American Journal of Medical Genetics, Part A, 2020, 182, 1725-1734.	0.7	12
18	Current management of hypertrophic cardiomyopathy. Current Treatment Options in Cardiovascular Medicine, 2008, 10, 496-504.	0.4	11

CAROLINE J COATS

#	Article	IF	CITATIONS
19	Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK. Advances in Therapy, 2022, 39, 2292-2301.	1.3	11
20	The vital role of exercise testing in hypertrophic cardiomyopathy. International Journal of Cardiology, 2018, 271, 200-201.	0.8	2
21	History of the British Cardiovascular Society. Heart, 2022, 108, 761-766.	1.2	2
22	The collapsing pulse. British Journal of Hospital Medicine (London, England: 2005), 2012, 73, C78-C80.	0.2	1
23	Hypertrophic Cardiomyopathy—Need for Gene-Specific Treatment?—Reply. JAMA Cardiology, 2019, 4, 831.	3.0	Ο
24	Arrhythmogenic Cardiomyopathy—Further Insight into the Clinical Spectrum of Desmoplakin Disease. Neurology International, 2021, 11, 219-229.	0.2	0